Open AccessIntrapartum Single-Dose Carbamazepine Reduces Nevirapine Levels Faster and May Decrease Resistance After a Single Dose of Nevirapine for Perinatal HIV Prevention
Author(s) -
Eva Muro,
Quirine Fillekes,
Elton R. Kisanga,
Rafaëlla F. A. L'homme,
Sue Aitken,
Godfrey Mariki,
A.J.A.M. van der Ven,
W.M.V. Dolmans,
Rob Schuurman,
A.S. Walker,
Diana M. Gibb,
David M. Burger
Publication year - 2012
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0b013e31824234d8
Subject(s) - nevirapine , medicine , interquartile range , pregnancy , carbamazepine , confidence interval , lamivudine , obstetrics , gastroenterology , human immunodeficiency virus (hiv) , hepatitis b virus , immunology , viral load , antiretroviral therapy , biology , virus , psychiatry , epilepsy , genetics
World Health Organization guidelines recommend zidovudine + lamivudine for 7 days from labor onset in HIV-infected women receiving single-dose nevirapine (sdNVP) to cover prolonged subtherapeutic nevirapine concentrations. Although effective, this is complicated and does not eliminate resistance; alternative strategies could add benefit.